Mr. John R Fratianni, DNAP, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 15844 Devonwood Way, San Lorenzo, CA 94580 Phone: 919-740-3490 |
News Archive
People with a known, high risk for Alzheimer's disease develop abnormal brain function even before the appearance of telltale amyloid plaques that are characteristic of the disease, according to a new study.
The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The organizations made the announcement in a joint letter to Congress and during an audio news conference with Senator Michael Bennet (D-CO), who will introduce this drug safety legislation.
Health-conscious people know that high levels of total cholesterol and LDL cholesterol (the so-called "bad" cholesterol) can increase the risk of heart attacks. Now scientists are reporting that another form of cholesterol called oxycholesterol - virtually unknown to the public - may be the most serious cardiovascular health threat of all. Scientists from China presented one of the first studies on the cholesterol-boosting effects of oxycholesterol here today at the 238th National Meeting of the American Chemical Society. The researchers hope their findings raise public awareness about oxycholesterol, including foods with the highest levels of the substance and other foods that can combat oxycholesterol's effects.
To make tumors more sensitive to the killing power of radiation is a key aspiration for many radiation oncologists. Researchers at Washington University School of Medicine in St. Louis have uncovered new information that leads them closer to that goal.
A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.
› Verified 9 days ago